Swiss-based upstart marches toward the clinic with a unique approach to fibrosis treatment
For more than 10 years, Thomas Baumert has been carefully studying a protein called Claudin-1 (CLDN1) for its role in fibrosis. Now, hot off a $67 million raise, he’s racing to the clinic with a monoclonal antibody he hopes can reverse kidney and liver disease.
Alentis Therapeutics, a biotech cross-bred in France and Switzerland, unveiled a Series B round early Tuesday morning that it will use to advance its lead candidate ALE.F02 into the clinic at the end of this year. The company launched in 2019 with a $13.2 million round led by two Swiss VC funds, BioMedPartners and BB Pureos Bioventures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
